Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. NASDAQ:IMMX
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immix Biopharma reports 89% interim response rate in NEXICART-2
Immix Biopharma said its interim update across all NEXICART-2 patients showed an 89% complete response rate, with MRD-negativity suggesting potential to reach up to a 98% complete response rate, supporting potential best-in-class therapy for relapsed/refractory AL amyloidosis.